Merck's Ace Keytruda Flunks Key Phase III Stomach Cancer Study
Novartis Oncology Head to Retire for Personal Reasons
These 2 Startups are Amgen's 2017 Golden Ticket Winners
How Amicus CEO Personally Appealed to FDA Head to Get Migalastat Back on Track
Boehringer CFO Quits After 16 Months on the Job Over Differences in Strategy
Asklepios BioPharma Launches New Biotech Actus Therapeutics
Biotechs Drool as VC Firm Andreessen Horowitz Doubles Down on the Life Sciences With New $450M Fund
Bay Area Rigel's CFO to Exit, Effective Dec. 31, 2017
Why AbbVie's Booming 2017 Could Continue in 2018
In the Nick of Time: Galapagos Nabs Co-Promotion Filgotinib Deal With Gilead
Suitors Line Up for Merck KGaA's $4.7B Consumer Health Biz
Finally Some Good News as the FDA Lifts Hold on Sanofi, Alnylam's Fitusiran
Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active...